Journal
VACCINES
Volume 9, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9030203
Keywords
PPV23; PCV13; OPKA titers; invasive pneumococcal disease; biological therapy; anti-TNF alpha; rituximab; tocilizumab; autoimmune inflammatory diseases
Categories
Funding
- Sociedad Madrilena de Reumatologia (SORCOM)/MSD
- Pfizer
- Ministerio de Economia, Industria y Competitividad [SAF2017-83388]
Ask authors/readers for more resources
Patients with different autoimmune inflammatory diseases on biological therapy are at risk of pneumococcal disease. The study showed that a protocol combining PCV13 and PPV23 vaccines can help achieve functional antibodies against pneumococcal serotypes. Among the different biological therapies used, etanercept was associated with achieving higher OPKA titers, while rituximab did not lead to a worse immune response compared to other agents.
Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNF alpha, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available